Theravance (THRX) 9.81 $THRX The 3 Most Importa
Post# of 273257
Posted On: 09/04/2016 7:14:27 AM
Theravance (THRX) 9.81 $THRX
The 3 Most Important Numbers When GlaxoSmithKline Reports Its Fourth-Quarter Results
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 29, 1:02PM CST
Image source: GlaxoSmithKline. Among Big Pharma, no drugmaker in particular has been given a reprieve from the patent cliff. However, U.K.-based GlaxoSmithKline was just late to the party. Whereas most of GlaxoSmithKline's peers dealt with...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28), NVS: 79.38 (+1.11)
Theravance Inc. Stock Was Up 14% in December -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jan 10, 11:07AM CST
What : Shares of Theravance Inc , a healthcare royalty company, put up another greatly monthly performance as the company's stock moved more than 14% higher during the month of December, according to data from S&P Capital IQ . So...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28)
Theravance, Inc. Announces Name Change to Innoviva, Inc.
Marketwired - Fri Jan 08, 7:00AM CST
Theravance, Inc. (NASDAQ: THRX), a healthcare-focused asset management company, today announced that it changed its name to Innoviva, Inc., effective January 7, 2016. In addition to Innoviva's new name, the company has also unveiled a new corporate identity and website, available at www.inva.com.
INVA: 11.09 (+0.02), THRX: 9.81 (+0.04)
Will 2016 Be GlaxoSmithKline plc's Best Year Yet?
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 04, 8:59AM CST
Image source: GlaxoSmithKline. Although the broad-based market was relatively flat this year, some investors are certainly happy to put 2015 in the rearview mirror. Shareholders of U.K.-based pharma giant GlaxoSmithKline are a good example. A...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28), NVS: 79.38 (+1.11)
Theravance Up 17.4% Since SmarTrend Uptrend Call (THRX)
Comtex SmarTrend(R) - Thu Dec 31, 2:10PM CST
SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 17.38% as of today's recent price of $10.67.
THRX: 9.81 (+0.04)
SmarTrend Watching for Potential Pullback in Shares of Theravance After 3.82% Gain
Comtex SmarTrend(R) - Mon Dec 28, 5:23PM CST
Theravance (NASDAQ:THRX) traded in a range yesterday that spanned from a low of $10.41 to a high of $10.91. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $10.75 on volume of 825,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THRX: 9.81 (+0.04)
The Best GlaxoSmithKline plc Headlines in 2015
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 28, 1:34PM CST
Image source: GlaxoSmithKline via Flickr. As the year comes to a close, the only certainty shareholders of U.K.-based pharmaceutical giant GlaxoSmithKline have known this year is constant uncertainty. It seems like there isn't a Big Pharma...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28), NVS: 79.38 (+1.11)
Theravance Shares Up 16.3% Since SmarTrend's Buy Recommendation (THRX)
Comtex SmarTrend(R) - Thu Dec 24, 10:26AM CST
SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 16.28% as of today's recent price of $10.57.
THRX: 9.81 (+0.04)
Uptrend Call Working As Theravance Stock Rises 16.3% (THRX)
Comtex SmarTrend(R) - Thu Dec 24, 10:22AM CST
SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 16.28% as of today's recent price of $10.57.
THRX: 9.81 (+0.04)
Will GlaxoSmithKline plc Raise Its Dividend in 2016?
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 21, 9:39AM CST
Image source: GlaxoSmithKline. It's been a rough 2015 for Big Pharma stocks, which have been whipsawed for much of the year, but the one solace that most large drug developers continue to offer their investors is an above-average dividend yield...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28), NVS: 79.38 (+1.11)
GlaxoSmithKline plc's Best Drug in 2015
Sean Williams, The Motley Fool - Motley Fool - Tue Dec 15, 7:21AM CST
Image source: GlaxoSmithKline via Flickr. It's been something of a rough year for U.K.-based pharmaceutical giant GlaxoSmithKline . Through Dec. 9 the Market Vectors Pharmaceutical ETF has been flat for the year, but shareholders of...
GILD: 76.89 (-0.53), THRX: 9.81 (+0.04), GSK: 44.26 (+1.28)
Theravance, Inc. Announces Preliminary Results of Tender Offer
Marketwired - Wed Dec 02, 6:00AM CST
Theravance, Inc. (NASDAQ: THRX) today announced the preliminary results of its "modified Dutch auction" tender offer, which expired at 5:00 P.M., New York City time, on Tuesday, December 1, 2015. Theravance intends to continue implementing the previously announced share repurchase plan through open market purchases, and may also repurchase shares through private transactions, exchange offers, additional tender offers or other means.
THRX: 9.81 (+0.04)
5 Things GlaxoSmithKline PLC Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 19, 8:16AM CST
Image source: GlaxoSmithKline. Three weeks ago, U.K.-based pharmaceutical giant GlaxoSmithKline reported its third-quarter results and handily clobbered Wall Street's profit projections, to the surprise of many. For those who may have missed...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28), NVS: 79.38 (+1.11)
Why Theravance Inc. Vaulted 15% Higher in October
Brian Feroldi, The Motley Fool - Motley Fool - Tue Nov 17, 6:51AM CST
What: Shares of Theravance , a healthcare royalty company, bounced back from their huge downward move in September , moving more than 15% higher during the month of October, according to data from S&P Capital IQ . So what: Investors...
THRX: 9.81 (+0.04)
Theravance to Present at Two Upcoming Investor Conferences in November
Marketwired - Wed Nov 04, 3:06PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, will present at two upcoming conferences in November 2015:
THRX: 9.81 (+0.04)
Theravance announces launch of self-tender offer for up to USD75m of common stock
M2 - Mon Nov 02, 5:04AM CST
Bio-pharmaceutical company Theravance (NASDAQ:THRX) revealed on Friday that it has commenced a "modified Dutch auction" tender offer for up to USD75m of its common stock.
THRX: 9.81 (+0.04)
Theravance, Inc. Announces Commencement of Self-Tender Offer for up to $75,000,000 of Its Common Stock
Marketwired - Fri Oct 30, 5:00AM CDT
Theravance, Inc. (NASDAQ: THRX) today announced that it is commencing its previously announced "modified Dutch auction" tender offer for up to $75,000,000 of its common stock at a price per share not less than $8.50 and not greater than $9.25. The tender offer will expire at 5:00 P.M., New York City time, on Tuesday, December 1, 2015, unless extended by the company. Tenders of shares must be made on or prior to the expiration of the tender offer and may be withdrawn at any time prior to the expiration of the tender offer, in each case, in accordance with the procedures described in the tender offer materials.
THRX: 9.81 (+0.04)
Theravance's Q3 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Thu Oct 29, 12:19PM CDT
Theravance (THRX) reported a third quarter loss of 4 cents per share along with total revenues of $13.6 million.
AZN: 33.31 (+0.71), AMAG: 23.66 (-0.05), GSK: 44.26 (+1.28), THRX: 9.81 (+0.04)
Why Shares of Theravance Inc Dropped 49% in September
Brian Feroldi, The Motley Fool - Motley Fool - Sun Oct 25, 2:03PM CDT
Shares of Theravance , a healthcare royalty management company for a focus on respiratory products, were down big during September after the company and its partner GlaxoSmithKline PLC released disappointing clinical news. Are the shares a buy...
IBB: 280.61 (-0.83), THRX: 9.81 (+0.04), GSK: 44.26 (+1.28)
The 3 Most Important Numbers When GlaxoSmithKline Reports Its Fourth-Quarter Results
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 29, 1:02PM CST
Image source: GlaxoSmithKline. Among Big Pharma, no drugmaker in particular has been given a reprieve from the patent cliff. However, U.K.-based GlaxoSmithKline was just late to the party. Whereas most of GlaxoSmithKline's peers dealt with...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28), NVS: 79.38 (+1.11)
Theravance Inc. Stock Was Up 14% in December -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jan 10, 11:07AM CST
What : Shares of Theravance Inc , a healthcare royalty company, put up another greatly monthly performance as the company's stock moved more than 14% higher during the month of December, according to data from S&P Capital IQ . So...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28)
Theravance, Inc. Announces Name Change to Innoviva, Inc.
Marketwired - Fri Jan 08, 7:00AM CST
Theravance, Inc. (NASDAQ: THRX), a healthcare-focused asset management company, today announced that it changed its name to Innoviva, Inc., effective January 7, 2016. In addition to Innoviva's new name, the company has also unveiled a new corporate identity and website, available at www.inva.com.
INVA: 11.09 (+0.02), THRX: 9.81 (+0.04)
Will 2016 Be GlaxoSmithKline plc's Best Year Yet?
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 04, 8:59AM CST
Image source: GlaxoSmithKline. Although the broad-based market was relatively flat this year, some investors are certainly happy to put 2015 in the rearview mirror. Shareholders of U.K.-based pharma giant GlaxoSmithKline are a good example. A...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28), NVS: 79.38 (+1.11)
Theravance Up 17.4% Since SmarTrend Uptrend Call (THRX)
Comtex SmarTrend(R) - Thu Dec 31, 2:10PM CST
SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 17.38% as of today's recent price of $10.67.
THRX: 9.81 (+0.04)
SmarTrend Watching for Potential Pullback in Shares of Theravance After 3.82% Gain
Comtex SmarTrend(R) - Mon Dec 28, 5:23PM CST
Theravance (NASDAQ:THRX) traded in a range yesterday that spanned from a low of $10.41 to a high of $10.91. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $10.75 on volume of 825,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THRX: 9.81 (+0.04)
The Best GlaxoSmithKline plc Headlines in 2015
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 28, 1:34PM CST
Image source: GlaxoSmithKline via Flickr. As the year comes to a close, the only certainty shareholders of U.K.-based pharmaceutical giant GlaxoSmithKline have known this year is constant uncertainty. It seems like there isn't a Big Pharma...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28), NVS: 79.38 (+1.11)
Theravance Shares Up 16.3% Since SmarTrend's Buy Recommendation (THRX)
Comtex SmarTrend(R) - Thu Dec 24, 10:26AM CST
SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 16.28% as of today's recent price of $10.57.
THRX: 9.81 (+0.04)
Uptrend Call Working As Theravance Stock Rises 16.3% (THRX)
Comtex SmarTrend(R) - Thu Dec 24, 10:22AM CST
SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 16.28% as of today's recent price of $10.57.
THRX: 9.81 (+0.04)
Will GlaxoSmithKline plc Raise Its Dividend in 2016?
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 21, 9:39AM CST
Image source: GlaxoSmithKline. It's been a rough 2015 for Big Pharma stocks, which have been whipsawed for much of the year, but the one solace that most large drug developers continue to offer their investors is an above-average dividend yield...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28), NVS: 79.38 (+1.11)
GlaxoSmithKline plc's Best Drug in 2015
Sean Williams, The Motley Fool - Motley Fool - Tue Dec 15, 7:21AM CST
Image source: GlaxoSmithKline via Flickr. It's been something of a rough year for U.K.-based pharmaceutical giant GlaxoSmithKline . Through Dec. 9 the Market Vectors Pharmaceutical ETF has been flat for the year, but shareholders of...
GILD: 76.89 (-0.53), THRX: 9.81 (+0.04), GSK: 44.26 (+1.28)
Theravance, Inc. Announces Preliminary Results of Tender Offer
Marketwired - Wed Dec 02, 6:00AM CST
Theravance, Inc. (NASDAQ: THRX) today announced the preliminary results of its "modified Dutch auction" tender offer, which expired at 5:00 P.M., New York City time, on Tuesday, December 1, 2015. Theravance intends to continue implementing the previously announced share repurchase plan through open market purchases, and may also repurchase shares through private transactions, exchange offers, additional tender offers or other means.
THRX: 9.81 (+0.04)
5 Things GlaxoSmithKline PLC Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 19, 8:16AM CST
Image source: GlaxoSmithKline. Three weeks ago, U.K.-based pharmaceutical giant GlaxoSmithKline reported its third-quarter results and handily clobbered Wall Street's profit projections, to the surprise of many. For those who may have missed...
THRX: 9.81 (+0.04), GSK: 44.26 (+1.28), NVS: 79.38 (+1.11)
Why Theravance Inc. Vaulted 15% Higher in October
Brian Feroldi, The Motley Fool - Motley Fool - Tue Nov 17, 6:51AM CST
What: Shares of Theravance , a healthcare royalty company, bounced back from their huge downward move in September , moving more than 15% higher during the month of October, according to data from S&P Capital IQ . So what: Investors...
THRX: 9.81 (+0.04)
Theravance to Present at Two Upcoming Investor Conferences in November
Marketwired - Wed Nov 04, 3:06PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, will present at two upcoming conferences in November 2015:
THRX: 9.81 (+0.04)
Theravance announces launch of self-tender offer for up to USD75m of common stock
M2 - Mon Nov 02, 5:04AM CST
Bio-pharmaceutical company Theravance (NASDAQ:THRX) revealed on Friday that it has commenced a "modified Dutch auction" tender offer for up to USD75m of its common stock.
THRX: 9.81 (+0.04)
Theravance, Inc. Announces Commencement of Self-Tender Offer for up to $75,000,000 of Its Common Stock
Marketwired - Fri Oct 30, 5:00AM CDT
Theravance, Inc. (NASDAQ: THRX) today announced that it is commencing its previously announced "modified Dutch auction" tender offer for up to $75,000,000 of its common stock at a price per share not less than $8.50 and not greater than $9.25. The tender offer will expire at 5:00 P.M., New York City time, on Tuesday, December 1, 2015, unless extended by the company. Tenders of shares must be made on or prior to the expiration of the tender offer and may be withdrawn at any time prior to the expiration of the tender offer, in each case, in accordance with the procedures described in the tender offer materials.
THRX: 9.81 (+0.04)
Theravance's Q3 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Thu Oct 29, 12:19PM CDT
Theravance (THRX) reported a third quarter loss of 4 cents per share along with total revenues of $13.6 million.
AZN: 33.31 (+0.71), AMAG: 23.66 (-0.05), GSK: 44.26 (+1.28), THRX: 9.81 (+0.04)
Why Shares of Theravance Inc Dropped 49% in September
Brian Feroldi, The Motley Fool - Motley Fool - Sun Oct 25, 2:03PM CDT
Shares of Theravance , a healthcare royalty management company for a focus on respiratory products, were down big during September after the company and its partner GlaxoSmithKline PLC released disappointing clinical news. Are the shares a buy...
IBB: 280.61 (-0.83), THRX: 9.81 (+0.04), GSK: 44.26 (+1.28)
(0)
(0)Scroll down for more posts ▼